Immunotherapy in NSCLC Patients with Brain Metastases

被引：21

作者：

Buriolla, Silvia ^{[1
]}

Pelizzari, Giacomo ^{[2
]}

Corvaja, Carla ^{[1
]}

Alberti, Martina ^{[1
]}

Targato, Giada ^{[1
]}

Bortolot, Martina ^{[1
]}

Torresan, Sara ^{[1
]}

Cortiula, Francesco ^{[2
]}

Fasola, Gianpiero ^{[2
]}

Follador, Alessandro ^{[2
]}

机构：

[1] Univ Udine, Dept Med DAME, I-33100 Udine, Italy

[2] Azienda Sanitaria Univ Friuli Cent ASUFC, Dept Oncol, I-33100 Udine, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 13期

关键词：

NSCLC; immunotherapy; brain; metastases; CELL LUNG-CANCER; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; 1ST-LINE TREATMENT; POOLED ANALYSIS; ITALIAN COHORT; PEMBROLIZUMAB; CHEMOTHERAPY; BLOCKADE; MELANOMA;

D O I：

10.3390/ijms23137068

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcomes, although patients with BMs are mostly underrepresented in randomized clinical trials. Moreover, the safety and activity of ICIs and radiotherapy combinations compared with single-agent or sequential modalities is still under evaluation to establish the optimal management of these patients. The aim of this review is to summarize the state-of-the-art of clinical evidence of ICIs intracranial activity and the main challenges of incorporating these agents in the treatment armamentarium of NSCLC patients with BMs.

引用

页数：12

共 76 条

[31] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[32] Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors [J].

Hendriks, Lizza E. L. ;

Henon, Clemence ;

Auclin, Edouard ;

Mezquita, Laura ;

Ferrara, Roberto ;

Audigier-Valette, Clarisse ;

Mazieres, Julien ;

Lefebvre, Corentin ;

Rabeau, Audrey ;

Le Moulec, Sylvestre ;

Cousin, Sophie ;

Duchemann, Boris ;

le Pechoux, Cecile ;

Botticella, Angela ;

Ammari, Samy ;

Gazzah, Anas ;

Caramella, Caroline ;

Adam, Julien ;

Lechapt, Emmanuele ;

Planchard, David ;

De Ruysscher, Dirk ;

Dingemans, Anne-Marie ;

Besse, Benjamin .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1244-1254

[33] Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer [J].

Jablonska, Paola Anna ;

Bosch-Barrera, Joaquim ;

Serrano, Diego ;

Valiente, Manuel ;

Calvo, Alfonso ;

Aristu, Javier .

CANCERS, 2021, 13 (09)

[34] Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors [J].

Kim, Ryul ;

Keam, Bhumsuk ;

Kim, Sehui ;

Kim, Miso ;

Kim, Se Hyun ;

Kim, Jin Wook ;

Kim, Yu Jung ;

Kim, Tae Min ;

Jeon, Yoon Kyung ;

Kim, Dong-Wan ;

Chung, Doo Hyun ;

Lee, Jong Seok ;

Heo, Dae Seog .

BMC CANCER, 2019, 19 (1)

[35] Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas [J].

Kim, Sehui ;

Koh, Jaemoon ;

Kwon, Dohee ;

Keam, Bhumsuk ;

Go, Heounjeong ;

Kim, Young A. ;

Jeon, Yoon Kyung ;

Chung, Doo Hyun .

EUROPEAN JOURNAL OF CANCER, 2017, 75 :141-149

[36] The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis [J].

Kotecha, Rupesh ;

Kim, Joseph M. ;

Miller, Jacob A. ;

Juloori, Aditya ;

Chao, Samuel T. ;

Murphy, Erin S. ;

Peereboom, David M. ;

Mohammadi, Alireza M. ;

Barnett, Gene H. ;

Vogelbaum, Michael A. ;

Angelov, Lilyana ;

Suh, John H. ;

Ahluwalia, Manmeet S. .

NEURO-ONCOLOGY, 2019, 21 (08) :1060-1068

[37] EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours [J].

Le Rhun, E. ;

Guckenberger, M. ;

Smits, M. ;

Dummer, R. ;

Bachelot, T. ;

Sahm, F. ;

Galldiks, N. ;

de Azambuja, E. ;

Berghoff, A. S. ;

Metellus, P. ;

Peters, S. ;

Hong, Y-K ;

Winkler, F. ;

Schadendorf, D. ;

van den Bent, M. ;

Seoane, J. ;

Stahel, R. ;

Minniti, G. ;

Wesseling, P. ;

Weller, M. ;

Preusser, M. .

ANNALS OF ONCOLOGY, 2021, 32 (11) :1332-1347

[38] Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data [J].

Lehrer, Eric J. ;

Peterson, Jennifer ;

Brown, Paul D. ;

Sheehan, Jason P. ;

Quinones-Hinojosa, Alfredo ;

Zaorsky, Nicholas G. ;

Trifiletti, Daniel M. .

RADIOTHERAPY AND ONCOLOGY, 2019, 130 :104-112

[39] The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC [J].

Manegold, Christian ;

Dingemans, Anne-Marie C. ;

Gray, Jhanelle E. ;

Nakagawa, Kazuhiko ;

Nicolson, Marianne ;

Peters, Solange ;

Reck, Martin ;

Wu, Yi-Long ;

Brustugun, Odd Terje ;

Crino, Lucio ;

Felip, Enriqueta ;

Fennell, Dean ;

Garrido, Pilar ;

Huber, Rudolf M. ;

Marabelle, Aurelien ;

Moniuszko, Marcin ;

Mornex, Francoise ;

Novello, Silvia ;

Papotti, Mauro ;

Perol, Maurice ;

Smit, Egbert F. ;

Syrigos, Kostas ;

van Meerbeeck, Jan P. ;

van Zandwijk, Nico ;

Yang, James Chih-Hsin ;

Zhou, Caicun ;

Vokes, Everett .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :194-207

[40] Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 [J].

Mans, Aaron S. ;

Herbst, Roy S. ;

de Castro Jr, Gilberto ;

Hui, Rina ;

Peled, Nir ;

Kim, Dong-Wan ;

Novello, Silvia ;

Satouchi, Miyako ;

Wu, Yi-Long ;

Garon, Edward B. ;

Reck, Martin ;

Robinson, Andrew G. ;

Samkari, Ayman ;

Piperdi, Bilal ;

Ebiana, Victoria ;

Lin, Jianxin ;

Mok, Tony S. K. .

JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (08)

← 1 2 3 4 5 6 7 8 →